ImmuCell Corporation - Asset Resilience Ratio
ImmuCell Corporation (ICCC) has an Asset Resilience Ratio of 0.11% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2021)
This chart shows how ImmuCell Corporation's Asset Resilience Ratio has changed over time. Check ICCC strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down ImmuCell Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ICCC market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.40K | 0.11% |
| Total Liquid Assets | $50.40K | 0.11% |
Asset Resilience Insights
- Limited Liquidity: ImmuCell Corporation maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ImmuCell Corporation Industry Peers by Asset Resilience Ratio
Compare ImmuCell Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for ImmuCell Corporation (2002–2021)
The table below shows the annual Asset Resilience Ratio data for ImmuCell Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $-468.00 | $44.47 Million | -2.47pp |
| 2020-12-31 | 2.47% | $996.50K | $40.35 Million | -3.94pp |
| 2019-12-31 | 6.41% | $2.48 Million | $38.69 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $34.30 Million | -- |
| 2016-12-31 | 22.16% | $5.47 Million | $24.70 Million | -8.41pp |
| 2015-12-31 | 30.57% | $4.46 Million | $14.60 Million | +8.05pp |
| 2014-12-31 | 22.52% | $2.49 Million | $11.05 Million | -4.71pp |
| 2013-12-31 | 27.23% | $2.98 Million | $10.96 Million | +6.93pp |
| 2012-12-31 | 20.31% | $2.24 Million | $11.03 Million | -17.70pp |
| 2011-12-31 | 38.01% | $4.18 Million | $10.99 Million | +8.00pp |
| 2010-12-31 | 30.02% | $3.23 Million | $10.75 Million | -6.14pp |
| 2009-12-31 | 36.16% | $3.61 Million | $9.98 Million | -1.90pp |
| 2008-12-31 | 38.05% | $3.85 Million | $10.13 Million | -2.46pp |
| 2007-12-31 | 40.52% | $4.22 Million | $10.41 Million | -5.82pp |
| 2006-12-31 | 46.33% | $5.27 Million | $11.36 Million | +6.66pp |
| 2005-12-31 | 39.68% | $3.95 Million | $9.96 Million | +10.82pp |
| 2004-12-31 | 28.85% | $2.75 Million | $9.53 Million | +18.00pp |
| 2003-12-31 | 10.85% | $888.32K | $8.19 Million | +0.38pp |
| 2002-12-31 | 10.48% | $787.05K | $7.51 Million | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more